Category - Developments

Developments

Actinium reports ATNM-400 data showing potent efficacy in TNBC

Actinium Pharmaceuticals (NYSE American: ATNM) has announced compelling preclinical data for ATNM-400, a first-in-class Actinium-225 (AC-225) antibody radioconjugate, in hormone receptor positive (HR+), HER2 positive...

December 1, 2025

Developments

BiomX reports update on trial of BX004 in CF

BiomX (NYSE American: PHGE) has announced that the FDA is continuing its evaluation of the nebulizer device used for drug administration in the company’s Phase 2b trial of BX004 in patients with cystic fibrosis (CF)...

November 26, 2025

Developments

Ripple enters into a collaboration with Bausch + Lomb

Closely held Ripple Therapeutics has announced that, earlier this year, it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb (NYSE/TSX: BLCO). Under the terms of the...

November 25, 2025

Developments

Clearmind’s DSMB recommends continuation of trial for CMND-100 in AUD; patient enrollment at TASMC kicks off

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that its independent Data and Safety Monitoring Board (DSMB) has completed a scheduled interim review of its ongoing FDA-approved multinational Phase I/IIa...

November 25, 2025

Developments

PetVivo launches AI platform reducing vet client acquisition costs by 50-89%

PetVivo Holdings (OTCQX: PETV; OTCID: PETVW) has announced the launch of PetVivo.ai that delivers a veterinary client acquisition cost of $42.53—a 50% to 89% reduction compared to $80 to $400 typically spent by...

November 25, 2025

Developments

Psyence reports major breakthrough in establishing pharmaceutical-grade ibogaine supply

Psyence BioMedical (NASDAQ: BPM) has announced it has sourced a sustainable supply of high-potency iboga bark—through its strategic partner, closely held PsyLabs—a significant achievement as the company prepares for the...

November 20, 2025

Developments

OS to spin off OSAH into a standalone company

OS Therapies (NYSE American: OSTX) has announced its intent to spin off OS Animal Health (OSAH)—the company’s wholly owned subsidiary developing OST-HER2 for canine osteosarcoma—into a standalone public company...

November 20, 2025

Developments

Profound celebrates The Hong Center’s 200th independent TULSA procedure; Dr. Mark Hong sees TULSA ultimately replacing radical prostatectomy as a first-line option for prostate cancer

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced today that The Hong Center Scottsdale, led by Dr. Y. Mark Hong of Integrative Urology in Phoenix, Arizona, has achieved a world-first milestone: 200 TULSA...

November 18, 2025

Developments

Quanterix highlights landmark study published in Brain validating dual approach for personalized MS monitoring

Quanterix (NASDAQ: QTRX) has announced the publication of a landmark study in the peer-reviewed scientific journal Brain, validating that multiplexed Simoa assays for Glial Fibrillary Acidic Protein (GFAP) and...

November 18, 2025

Developments

Vanda reports positive results for prevention of GLP-1 nausea with tradipitant

Vanda Pharmaceuticals (NASDAQ: VNDA) announced positive topline results from its randomized controlled clinical study evaluating tradipitant, an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of nausea...

November 18, 2025

Category - Developments

Subscribe